Day: May 25, 2022

Šiaulių Bankas AB, company code 112025254, address Tilžės str. 149, 76348 Šiauliai, Lithuania. On 24 May 2022 AB Šiaulių Bankas received the notification from the European Central Bank (ECB), that the Governing Council of the ECB has decided not to object to the appointment of Valdas Vitkauskas as an independent member of the Supervisory Council of Šiaulių Bankas AB. Valdas Vitkauskas has been elected to the Supervisory Council of Šiaulių Bankas at the General Meeting of Shareholders held on 30 March 2022. The decision of the meeting stipulates that he will take up the duties of the member of the Supervisory Council only with the permission of the supervisory authority. Valdas Vitkauskas is considered to be as an independent member of the Supervisory Council of Šiaulių Bankas AB from 1 June 2022. Additional information:Head of HRJurgita...

Company announcement no. 10 / 2022Schindellegi, Switzerland – 25 May 2022 Pursuant to the Market Abuse Regulation article 19, Trifork Holding AG (Swiss company registration number CHE-474.101.854) (“Trifork”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Trifork.1. Details of the person discharging managerial responsibilities/person closely associateda) Name Jørn Larsen2. Reason for the notificationa) Position/status CEOb) Initial notification/ Amendment Initial notification3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora) Name Trifork Holding AGb) LEI 8945004BYZKXPESTBL364.1 Details of the transaction(s):a) Description of the financial instrument, type of instrument Identification...

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th World Congress–   GENEVA, Switzerland May 25, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist. These data were featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders (SEUD) Congress held in Athens, Greece from May 18-21, 2022, and a poster presentation at the International Society of Gynecological Endocrinology (ISGE) 20th World Congress held in Florence, Italy from May 11-14, 2022. “The encouraging data presented at these...

WISeKey Announces that Casa de Alba Foundation, Luminaries 21, Pedro Sandoval, MS Porrima Blue Odyssey, Upeace, Fondacion UNOART & WISe.ART Collaborate at DAVOS 2022 to Support Global Efforts to Implement SDGs Geneva – May 25, 2022 – WISeKey International Holding (“WISeKey”, SIX: WIHN, NASDAQ: WKEY), a leading security Certificate Authority and provider of identity solutions, today announced its entire WISe.ART team will be hosted by CasperLabs to showcase the WISe.ART secured NFT marketplace at Avenue 69 in Davos from May 23 to 25, 2022. WISe.ART is much more than a secured vetted NFT marketplace. It cares about society and the planet and supports many environmentally friendly projects, projects which place humans at the heart of the action with a view to raise awareness and funds. WISe.ART aims to embrace...

Saint Herblain (France), May 25, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination. The trial included 408 participants aged 18 to 45 years. The safety profile shown in study VLA1553-302 was similar to the Phase 3 trial, VLA1553-3011. With a 96.0% seroprotection rate at Day 180, the immunogenicity profile from study VLA1553-301 was also...